About CINRYZE

What is CINRYZE?

CINRYZE was the first C1 esterase inhibitor (C1-INH) approved by the FDA to help prevent swelling attacks in children (6 years of age and older), teenagers and adults. Available since 2008, CINRYZE has successfully been used to help reduce the frequency, severity, and length of attacks in adolescent and adult patients. In pediatric patients (age 6 to 11), CINRYZE was shown to reduce the number of HAE attacks, lessen the severity of attacks, and reduce the use of acute treatment.

How does CINRYZE work?

Most people with HAE don't have enough of a protein called C1 esterase inhibitor (C1-INH), or this protein does not work correctly, which leads to a cascade of events in the body. This cascade causes another protein, called plasma kallikrein, to trigger the release of a third protein, called bradykinin. The release of too much bradykinin causes small blood vessels to release fluid in certain parts of the body, resulting in the localized swelling and pain of an HAE attack. CINRYZE^® (C1 esterase inhibitor [human]) increases plasma levels of C1-INH, thereby preventing the generation of excess bradykinin to reduce the risk of a swelling attack.